References
- FeniziaFDe LucaAPasqualeREGFR mutations in lung cancer: from tissue testing to liquid biopsyFuture Oncol201511111611162326043215
- OuSIAgarwalNAliSMHigh MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progressionLung Cancer201698596127393507
- SchildhausHUSchultheisAMRüschoffJMET amplification status in therapy-naïve adeno-and squamous cell carcinomas of the lungClin Cancer Res201521490791525492085
- OuSHPavlickDStephensPJGemonic analysis of non-small cell lung cancer (NSCLC) cases with focal and non-focal MET amplificationAbstract OA 12.08, IASLC 18th World Conference on Lung Cancer2017
- SchefflerMMerkelbach-BruseSBosMSpatial tumor heterogeneity in lung cancer with acquired epidermal growth factor receptor-tyrosine kinase inhibitor resistance: targeting high-level MET-amplification and EGFR T790M mutation occurring at different sites in the same patientJ Thorac Oncol2015106e40e4326001148
- GainorJFNiederstMJLennerzJKDramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplificationJ Thorac Oncol2016117e83e8526988570
- LiYQSongSSJiangSHZhangXYCombination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108CAnn Oncol201728102622262428961830
- YorkERVarella-GarciaMBangTJAisnerDLCamidgeDRTolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancerJ Thorac Oncol2017127e85e8828274743
- KangJChenH-JWangZOsimertinib and cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to crizotinibJ Thorac Oncol2018134e49e5329128427
- DengLKiedrowskiLARaveraEChengHHalmosBResponse to dual crizotinib and osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibitionJ Thorac Oncol2018139e169e17230166014
- ReungwetwattanaTLiangYZhuVOuS-HIThe race to target Met exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the WHO, the unknown, and the inevitableLung Cancer2017103273728024693
- KlempnerSJBorgheiAHakimianBAliSMOuS-HIIntracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastasesJ Thorac Oncol201712115215627693535
- SchrockABZhuVWHsiehWSReceptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitorsJ Thorac Oncol20181391312132329883838